AC Immune SA (STU:IMR)
€ 3.705 -0.3 (-7.49%) Market Cap: 376.55 Mil Enterprise Value: 270.11 Mil PE Ratio: 0 PB Ratio: 2.48 GF Score: 58/100

AC Immune SA at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 14, 2023 / 01:40PM GMT
Release Date Price: €2.24 (+1.77%)
Marc Goodman
SVB Securities - Analyst

Okay. Good morning, everybody. Welcome back to our next session of the SVB Securities Healthcare Conference. I'm Marc Goodman, one of the analysts here.

We're lucky enough to have the CEO of AC Immune, Andrea Pfeifer, with us. She's a Co-Founder of the company, which I believe was about 20 or so years ago, so something's been around. We've been tracking AC Immune for years now. We find them to be a leader in the space regarding science in Alzheimer's, diverse portfolio of candidates, multiple strong partnerships. So we've always been a big fan of what they're doing. Andrea is going to make some opening comments with slides, and then we'll have some time for questions afterwards.

Andrea, thank you so much for joining us again this year, and I'll turn it over to you.

Andrea Pfeifer
AC Immune SA - Co-Founder, CEO & Director

Yep, good morning. I'm excited to be here and talk about AC Immune, a company pioneering precision medicine in neurodegenerative diseases. Today, we'll take a very quick overview,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot